文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

妇科肿瘤术后盆腔放化疗期间腹泻与血清细胞因子的关联

The association between diarrhea and serum cytokines in patients with gynecologic cancer treated with surgery and pelvic chemoradiotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-06-09

结果显示放疗第5-6周时,≥2级腹泻患者的血清IL-6水平显著高于0-1级患者(6.771 ± 2.657 pg/mL vs. 3.396 ± 0.499 pg/mL,p = 0.046),而IL-1β和TNFα水平无变化。放化疗前腹泻和小肠最大剂量是放化疗诱发腹泻的独立预后因素。

要点

  • 盆腔放化疗期间≥2级腹泻患者第5-6周血清IL-6水平显著升高。
  • 血清IL-1β和TNFα水平在放化疗期间未见变化。
  • 放化疗前腹泻和小肠最大剂量是放化疗诱发腹泻的独立预后因素。

核心结论

  • 盆腔放化疗期间≥2级腹泻患者血清IL-6水平升高,而IL-1β和TNFα水平无变化。
  • 放疗相关因素和临床因素均影响盆腔放化疗期间腹泻的发生。

主要发现

  • 放化疗前,有无腹泻患者的细胞因子水平无差异。
  • 放化疗第5-6周,≥2级腹泻患者血清IL-6水平显著高于0-1级患者(6.771 ± 2.657 pg/mL vs. 3.396 ± 0.499 pg/mL,p = 0.046)。
  • 血清IL-1β和TNFα水平在放化疗期间未发生变化。
  • 多因素分析显示放化疗前腹泻和小肠最大剂量是放化疗诱发腹泻的独立预后因素。

关键数值与推荐

  • 腹泻分级按每周症状评估,≥2级腹泻定义为需关注的腹泻事件。
  • 血清细胞因子于放化疗前1周、第3周和第5-6周用免疫分析法检测。

临床怎么用

  • 盆腔放化疗期间监测血清IL-6水平可能有助于识别≥2级腹泻高风险患者。
  • 关注放化疗前已有腹泻及小肠最大剂量较高的患者,加强腹泻预防与管理。

局限性

  • 单中心前瞻性研究,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated whether serum cytokines including Interleukin (IL)-1β, IL-6 and tumor necrosis factor alpha (TNFα) are increased during pelvic chemoradiotherapy (CRT) in patients with gynecologic malignancies, and sought to identify prognostic factors for the development of diarrhea during pelvic CRT. MATERIALS AND METHODS: Patients with cervical or endometrial cancer receiving postoperative pelvic CRT were eligible for this prospective study. Patients were evaluated weekly during CRT for symptoms, including diarrhea and constipation. Serum cytokine levels were measured using immunoassays 1 week before CRT, and at week 3 and 5-6 during CRT. Radiotherapy-related parameters such as mean dose, minimum dose, and maximum dose to the small bowel were also analyzed. Multivariate logistic regression analysis was used to assess factors associated with development of enteritis symptoms. RESULTS: Twenty-six patients were enrolled, all of whom were eligible for symptom and dosimetric parameter evaluation; 24 were eligible for cytokine level measurement. Cytokine levels did not differ between patients with and without diarrhea before CRT. IL-6 levels increased during CRT, and were significantly higher in patients with diarrhea ≥grade 2 than in those with grade 0-1 at week 5-6 (6.771 ± 2.657 pg/mL vs. 3.396 ± 0.499 pg/mL, p = 0.046). Serum IL-1β and TNFα levels did not change during CRT. Diarrhea before CRT and the maximum dose to the small bowel were independent prognostic factors for CRT-induced diarrhea in the multivariate analysis. CONCLUSIONS: There was an increase of serum IL-6 levels in patients with ≥grade 2 diarrhea during pelvic CRT. Serum IL-1β and TNFα levels did not change during CRT. Radiotherapy-related and clinical factors affect the development of diarrhea during pelvic CRT.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Eom KY, Wee CW, Song C, et al. The association between diarrhea and serum cytokines in patients with gynecologic cancer treated with surgery and pelvic chemoradiotherapy. Clin Transl Radiat Oncol. 2021. PMID: 34159263. doi:10.1016/j.ctro.2021.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。